Safety and Efficacy Evaluation of Artemisinin-based Combination Therapy for the Treatment of Uncomplicated Plasmodium vivax Malaria

Objectives

This study will assess the proportion of adequate clinical and parasitological response and overall success or treatment failure at day 28, 42 and 63.

The study foresees the inclusion of 264 participants, which will be divided into 3 groups. The control group included 88 participants who will receive 150 mg Chloroquine + primaquine 15 mg orally for 7 consecutive days; Group 2 included 88 participants who will receive fixed-dose combination of artesunate and mefloquine, 100 +200 mg tablets + primaquine 15 mg orally for 7 consecutive days; group 3 included 88 participants who will receive fixed-dose combination of artemether and lumefantrine tablets 20 + 120 mg + primaquine 15 mg orally for 7 consecutive days.